Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for Huntington’s disease.
- Home |
- UniQure shares crash 40% as FDA rejects early approval path for Huntington’s gene therapy
UniQure shares crash 40% as FDA rejects early approval path for Huntington’s gene therapy
- March 2, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
